



Abbreviations

AEs	adverse events
BR	bendamustine and rituximab
BTK	Bruton's tyrosine kinase
BVR	bendamustine, bortezomib, rituximab
CAR T-cells	chimeric antigen receptor T-cell immunotherapy
CLL	chronic lymphocytic leukemia
CMV	cytomegalovirus
CR	complete remission
CRES	CAR T-cell–related encephalopathy syndrome
CRS	cytokine release syndrome
CVP	cyclophosphamide, vincristine, prednisone
DA-EPOCH-R	dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin + rituximab
DLBCL	diffuse large B-cell lymphoma
DO	duvelisib with obinutuzumab
DR	duvelisib with rituximab
FL	follicular lymphoma
LPL	lymphoplasmacytic lymphoma
MCL	mantle cell lymphoma
MZL	marginal zone lymphoma
ORR	overall response rate
OS	overall survival
PI3K	phosphatidylinositol-3-kinase
PFS	progression-free survival
PJP	pneumocystis jiroveci pneumonia
R-CHOP	rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone
SAEs	serious adverse events
SLL	small lymphocytic lymphoma